company background image
GNCA.Q logo

Genocea Biosciences OTCPK:GNCA.Q Stock Report

Last Price

US$0.0001

Market Cap

US$5.9k

7D

0%

1Y

-99.8%

Updated

23 May, 2023

Data

Company Financials

Genocea Biosciences, Inc.

OTCPK:GNCA.Q Stock Report

Market Cap: US$5.9k

GNCA.Q Stock Overview

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies.

GNCA.Q fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Genocea Biosciences, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Genocea Biosciences
Historical stock prices
Current Share PriceUS$0.0001
52 Week HighUS$0.099
52 Week LowUS$0.0001
Beta2.07
11 Month Change0%
3 Month Change-66.67%
1 Year Change-99.84%
33 Year Change-100.00%
5 Year Change-100.00%
Change since IPO-100.00%

Recent News & Updates

Recent updates

Here's Why Shareholders May Want To Be Cautious With Increasing Genocea Biosciences, Inc.'s (NASDAQ:GNCA) CEO Pay Packet

Jun 17
Here's Why Shareholders May Want To Be Cautious With Increasing Genocea Biosciences, Inc.'s (NASDAQ:GNCA) CEO Pay Packet

What Type Of Returns Would Genocea Biosciences'(NASDAQ:GNCA) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Feb 18
What Type Of Returns Would Genocea Biosciences'(NASDAQ:GNCA) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

How Much Of Genocea Biosciences, Inc. (NASDAQ:GNCA) Do Institutions Own?

Jan 14
How Much Of Genocea Biosciences, Inc. (NASDAQ:GNCA) Do Institutions Own?

Shareholder Returns

GNCA.QUS BiotechsUS Market
7D0%-0.7%-1.6%
1Y-99.8%19.8%30.8%

Return vs Industry: GNCA.Q underperformed the US Biotechs industry which returned -3.5% over the past year.

Return vs Market: GNCA.Q underperformed the US Market which returned 15.2% over the past year.

Price Volatility

Is GNCA.Q's price volatile compared to industry and market?
GNCA.Q volatility
GNCA.Q Average Weekly Movement1,251.8%
Biotechs Industry Average Movement9.6%
Market Average Movement6.0%
10% most volatile stocks in US Market14.9%
10% least volatile stocks in US Market2.9%

Stable Share Price: GNCA.Q's share price has been volatile over the past 3 months.

Volatility Over Time: GNCA.Q's weekly volatility has increased from 816% to 1252% over the past year.

About the Company

FoundedEmployeesCEOWebsite
200674Chip Clarkwww.genocea.com

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens.

Genocea Biosciences, Inc. Fundamentals Summary

How do Genocea Biosciences's earnings and revenue compare to its market cap?
GNCA.Q fundamental statistics
Market capUS$5.88k
Earnings (TTM)-US$37.19m
Revenue (TTM)US$1.91m

0.0x

P/S Ratio

0.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GNCA.Q income statement (TTM)
RevenueUS$1.91m
Cost of RevenueUS$0
Gross ProfitUS$1.91m
Other ExpensesUS$39.10m
Earnings-US$37.19m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.63
Gross Margin100.00%
Net Profit Margin-1,946.15%
Debt/Equity Ratio61.7%

How did GNCA.Q perform over the long term?

See historical performance and comparison